{"id":7255,"date":"2020-06-01T12:41:54","date_gmt":"2020-06-01T19:41:54","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7255"},"modified":"2021-03-24T12:42:36","modified_gmt":"2021-03-24T19:42:36","slug":"efficacy-and-safety-of-interferon-beta-1a-in-treatment-of-severe-covid-19-a-randomized-clinical-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/01\/efficacy-and-safety-of-interferon-beta-1a-in-treatment-of-severe-covid-19-a-randomized-clinical-trial\/","title":{"rendered":"Efficacy and Safety of Interferon Beta-1a in Treatment of Severe COVID-19 A Randomized Clinical Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><i><span data-contrast=\"none\">[pre-print, not peer reviewed]<\/span><\/i><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">Davoudi-Monfared et al<\/span><span data-contrast=\"auto\">.<\/span><span data-contrast=\"auto\">\u00a0report the results of a randomized trial<\/span><span data-contrast=\"auto\">\u00a0evaluating the efficacy and safety of\u00a0<\/span><span data-contrast=\"auto\">interferon<\/span><span data-contrast=\"auto\">\u00a0\u03b2-1a\u00a0<\/span><span data-contrast=\"auto\">(IFN)\u00a0<\/span><span data-contrast=\"auto\">in patients with severe COVID-19<\/span><span data-contrast=\"auto\">, which<\/span><span data-contrast=\"auto\">\u00a0showed no significant difference of time to clinical response between the IFN and the control groups (9.7\u00a0<\/span><span data-contrast=\"auto\">\u00b1<\/span><span data-contrast=\"auto\">\u00a05.8 vs. 8.3\u00a0<\/span><span data-contrast=\"auto\">\u00b1<\/span><span data-contrast=\"auto\">\u00a04.9 days).\u00a0<\/span><span data-contrast=\"auto\">The<\/span><span data-contrast=\"auto\">\u00a0IFN group had\u00a0<\/span><span data-contrast=\"auto\">a\u00a0<\/span><span data-contrast=\"auto\">higher discharge rate on day 14 and lower 28-day mortality (<\/span><span data-contrast=\"auto\">66.7% vs. 43.6%<\/span><span data-contrast=\"auto\">\u00a0and<\/span><span data-contrast=\"auto\">\u00a0<\/span><span data-contrast=\"auto\">19.0% vs. 38.5%<\/span><span data-contrast=\"auto\">, respectively<\/span><span data-contrast=\"auto\">).<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Davoudi-Monfared et al. (May 30, 2020). Efficacy and Safety of Interferon Beta-1a in Treatment of Severe COVID-19 A Randomized Clinical Trial. Pre-print\u00a0downloaded June 1 from<\/span><\/i><span data-contrast=\"auto\">\u00a0<\/span><a href=\"https:\/\/doi.org\/10.1101\/2020.05.28.20116467\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1101\/2020.05.28.20116467<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[pre-print, not peer reviewed]\u00a0Davoudi-Monfared et al.\u00a0report the results of a randomized trial\u00a0evaluating the efficacy and safety of\u00a0interferon\u00a0\u03b2-1a\u00a0(IFN)\u00a0in patients with severe COVID-19, which\u00a0showed no significant difference of time to clinical response between the IFN and the control groups (9.7\u00a0\u00b1\u00a05.8 vs. 8.3\u00a0\u00b1\u00a04.9 days).\u00a0The\u00a0IFN group had\u00a0a\u00a0higher discharge rate on day 14 and lower 28-day mortality (66.7% vs. 43.6%\u00a0and\u00a019.0%&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/01\/efficacy-and-safety-of-interferon-beta-1a-in-treatment-of-severe-covid-19-a-randomized-clinical-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-7255","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7255"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7255\/revisions"}],"predecessor-version":[{"id":7256,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7255\/revisions\/7256"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7255"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}